Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NYSE:FAII NASDAQ:HITI NASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.75-4.2%$2.05$0.87▼$6.37$290.48M0.991.01 million shs6.13 million shsFAIIFortress Value Acquisition Corp. II$9.36$9.01▼$13.05$72.45MN/A845,837 shs376,711 shsHITIHigh Tide$3.43+1.5%$2.74$1.64▼$3.65$294.32M0.58998,578 shs683,561 shsMREOMereo BioPharma Group$1.85+1.6%$1.79$1.47▼$4.72$289.38M0.47897,251 shs766,362 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-4.18%-8.64%+26.20%+78.57%-52.67%FAIIFortress Value Acquisition Corp. II0.00%0.00%0.00%0.00%-70.93%HITIHigh Tide+1.48%-0.29%+39.43%+50.44%+54.50%MREOMereo BioPharma Group+1.65%+4.52%+6.94%-32.97%-60.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.75-4.2%$2.05$0.87▼$6.37$290.48M0.991.01 million shs6.13 million shsFAIIFortress Value Acquisition Corp. II$9.36$9.01▼$13.05$72.45MN/A845,837 shs376,711 shsHITIHigh Tide$3.43+1.5%$2.74$1.64▼$3.65$294.32M0.58998,578 shs683,561 shsMREOMereo BioPharma Group$1.85+1.6%$1.79$1.47▼$4.72$289.38M0.47897,251 shs766,362 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-4.18%-8.64%+26.20%+78.57%-52.67%FAIIFortress Value Acquisition Corp. II0.00%0.00%0.00%0.00%-70.93%HITIHigh Tide+1.48%-0.29%+39.43%+50.44%+54.50%MREOMereo BioPharma Group+1.65%+4.52%+6.94%-32.97%-60.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1751.52% UpsideFAIIFortress Value Acquisition Corp. II 0.00N/AN/AN/AHITIHigh Tide 3.33Buy$4.7538.48% UpsideMREOMereo BioPharma Group 3.20Buy$7.40300.00% UpsideCurrent Analyst Ratings BreakdownLatest FAII, HITI, ALEC, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025HITIHigh TideHaywood SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.507/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $5.006/18/2025HITIHigh TideRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.50 ➝ $5.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$81.13M3.43N/AN/A$1.29 per share2.13FAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/A$0.12 per shareN/AHITIHigh Tide$381.22M0.78$0.20 per share17.13$1.33 per share2.58MREOMereo BioPharma Group$500K588.30N/AN/A$0.39 per share4.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)FAIIFortress Value Acquisition Corp. II-$13.61MN/A0.00N/AN/AN/AN/AN/AN/AHITIHigh Tide-$3.19M-$0.08N/A42.88N/A-1.71%-6.45%-3.93%9/15/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)Latest FAII, HITI, ALEC, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/15/2025Q3 2025HITIHigh Tide-$0.01N/AN/AN/A$146.00 millionN/A8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million6/16/2025Q2 2025HITIHigh Tide-$0.02-$0.03-$0.01-$0.03$138.50 million$99.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AFAIIFortress Value Acquisition Corp. IIN/AN/AN/AN/AN/AHITIHigh TideN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78FAIIFortress Value Acquisition Corp. IIN/A0.090.09HITIHigh Tide0.301.570.97MREOMereo BioPharma GroupN/A8.138.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%FAIIFortress Value Acquisition Corp. II64.25%HITIHigh Tide4.52%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%FAIIFortress Value Acquisition Corp. IIN/AHITIHigh Tide12.44%MREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableFAIIFortress Value Acquisition Corp. IIN/A43.13 millionN/ANot OptionableHITIHigh Tide1,55087.08 million76.24 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableFAII, HITI, ALEC, and MREO HeadlinesRecent News About These CompaniesMereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Buy" by AnalystsSeptember 7, 2025 | americanbankingnews.comFrazier Life Sciences Management L.P. Buys 2,722,084 Shares of Mereo BioPharma Group plc - Sponsored ADR $MREOSeptember 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOSeptember 3, 2025 | prnewswire.comMereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Tema Etfs LLCAugust 30, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 29, 2025 | globenewswire.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Mereo BioPharma Group (NASDAQ:MREO) StockAugust 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 25, 2025 | globenewswire.comAberdeen Group plc Acquires New Holdings in Mereo BioPharma Group plc - Sponsored ADR $MREOAugust 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 21, 2025 | globenewswire.comCantor Fitzgerald Has Positive View of MREO FY2026 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Mereo BioPharma Group Reduced by AnalystAugust 17, 2025 | marketbeat.comTejara Capital Ltd Purchases 204,239 Shares of Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO)August 17, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comAnalysts Offer Predictions for MREO Q1 EarningsAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREOAugust 16, 2025 | prnewswire.comAnalysts Set Expectations for MREO Q3 EarningsAugust 16, 2025 | marketbeat.comMereo BioPharma Group (NASDAQ:MREO) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPSAugust 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFAII, HITI, ALEC, and MREO Company DescriptionsAlector NASDAQ:ALEC$2.75 -0.12 (-4.18%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.78 +0.03 (+1.24%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Fortress Value Acquisition Corp. II NYSE:FAIIFortress Value Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.High Tide NASDAQ:HITI$3.43 +0.05 (+1.48%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.51 +0.08 (+2.30%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Retail and Wholesale segments. It operates licensed retail cannabis stores; and provides data analytics services. In addition, the company manufactures and distributes consumption accessories. Further, it sells its products through online sales via e-commerce platform. The company offers its products under the Daily High Club, DankStop, FABCBD, GC, Nuleaf, Smoke Cartel, and Blessed CBD brands. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. High Tide Inc. was founded in 2009 and is headquartered in Calgary, Canada.Mereo BioPharma Group NASDAQ:MREO$1.85 +0.03 (+1.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.84 -0.01 (-0.54%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
